You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 205 No. 12, September 16, 1968 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Incidence of Leukemia Following Treatment of Hyperthyroidism

Preliminary Report of the Cooperative Thyrotoxicosis Therapy Follow-Up Study

Eugene L. Saenger, MD; George E. Thoma, MD; Edythalena A. Tompkins

JAMA. 1968;205(12):855-862.


Abstract

This study was conducted to test for an increase in the incidence of leukemia in hyperthyroid patients treated by radioactive iodine131I as compared to the incidence in patients treated differently. Of 36,000 patients from 26 medical centers, approximately 22,000 were treated with131I and about 14,000 were treated surgically or solely with antithyroid drugs. More than 96% of patients were followed up. Forty-four cases of leukemia occurred after, and 16 before, treatment. The incidence of leukemia in patients treated with131I for hyperthyroidism and the incidence in those treated surgically do not differ. Patients both undergoing surgery and receiving131I have a higher incidence of leukemia than any other treatment group. The observed mortality from leukemia for hyperthyroid patients is 50% higher than that of the US population.



Footnotes

For a complete list of participants, see page 862.

Reprint requests to 3231 Burnet Ave, Cincinnati 45229 (Dr. Saenger).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

An Optimal Treatment for Pediatric Graves' Disease Is Radioiodine
Rivkees and Dinauer
J. Clin. Endocrinol. Metab. 2007;92:797-800.
ABSTRACT | FULL TEXT  

Radioiodine Therapy for Multinodular Toxic Goiter
Nygaard et al.
Arch Intern Med 1999;159:1364-1368.
ABSTRACT | FULL TEXT  

Cancer Mortality Following Treatment for Adult Hyperthyroidism
Ron et al.
JAMA 1998;280:347-355.
ABSTRACT | FULL TEXT  

Radioiodine for Hyperthyroidism: Where Do We Stand After 50 Years?
Cooper
JAMA 1998;280:375-376.
FULL TEXT  

Breast Cancer in Hypothyroid Women Using Thyroid Supplements
Hoffman et al.
JAMA 1984;251:616-619.
ABSTRACT  

History of the Discovery and Early Use of Radioactive Iodine
Chapman
JAMA 1983;250:2042-2044.
ABSTRACT  

Incidence of Malignant Neoplasms of All Types in Patients With Graves' Disease
Munoz et al.
Arch Intern Med 1978;138:944-947.
ABSTRACT  

125I Therapy in Graves' Disease: Long-Term Results in 355 Patients
McDOUGALL and GREIG
ANN INTERN MED 1976;85:720-723.
ABSTRACT  

Thyroid Carcinoma After Exposure to Atomic Radiation: A Continuing Survey of a Fixed Population, Hiroshima and Nagasaki, 1958-1971
PARKER et al.
ANN INTERN MED 1974;80:600-604.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1968 American Medical Association. All Rights Reserved.